Forbes Recognizes ATELIER Playa Mujeres as the Best All-Inclusive Resort in Cancun for Foodies
Forbes recognized ATELIER Playa Mujeres as the 'Best All-Inclusive Resort in Cancun for Foodies' in its ranking of the 10 Best All-Inclusive Resorts in Cancun
'We are proud to be among Forbes' 10 Best All-Inclusive Resorts in Cancun, recognized thanks to our cutting-edge culinary experiences, from a Mexican cantina to breathtaking Caribbean Sea views.' — David Torres, Chief Commercial Officer of ATELIER de Hoteles
CANCUN, QUINTANA ROO, MEXICO, January 31, 2025 / EINPresswire.com / -- ATELIER Playa Mujeres ®, the 5+ star All-Suites Luxury Resort, an adults-only all-inclusive concept operated and marketed by ADH- ATELIER de Hoteles ®, has been selected by Forbes as the 'Best All-Inclusive Resort in Cancun for Foodies' in its recent ranking of the 10 Best All-Inclusive Resorts in Cancun.
The Forbes selection is made by a team of expert editors who carefully and thoroughly research and evaluate each resort. During this process, ATELIER Playa Mujeres® stood out for offering high-quality gastronomy across its 13 restaurants and 12 bars.
According to Forbes, the best all-inclusive resorts in Cancun inspire travelers to return to this beach destination year after year. The publication highlights that ATELIER Playa Mujeres® has a loyal guest base, thanks to its exclusive service and spacious, contemporary suites. Additionally, Forbes states that this resort 'will captivate travelers seeking high-quality restaurants, exclusive amenities, and luxury suites on a white-sand beach.'
ATELIER Playa Mujeres® immerses each guest in an atmosphere of sophistication, enhanced by remarkable amenities and services, elevating relaxation to a whole new level. Its world-class gastronomy and wellness spaces create the ideal environment to unwind and rejuvenate.
Marisa Steta
Facebook
TikTok
Legal Disclaimer:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Jim Cramer on Chipotle Mexican Grill (CMG): 'I Think Chipotle's Making a Comeback'
We recently published a list of . In this article, we are going to take a look at where Chipotle Mexican Grill, Inc. (NYSE:CMG) stands against other stocks that Jim Cramer discusses. Inquiring about Chipotle Mexican Grill, Inc. (NYSE:CMG), a caller noted that the stock is somewhat 'lacking'. In response, Cramer said: 'Hey, come on. I had a really good day… and suddenly, I see Chipotle starting to roll. I mean, the stock is up $2. You know I'm pulling for Scott Boatwright. I think we're in good shape. I think we, I gotta tell you, this one's been just treading water because maybe they raised prices too much. But I think Chipotle's making a comeback. I would want to be a buyer…' Chipotle Mexican Grill (NYSE:CMG) owns and runs restaurants serving a variety of Mexican-inspired dishes like burritos, tacos, and salads. The company also offers delivery and related services through its app and website. Toward the end of April, when Cramer was asked about the company, he said: 'Great question. I would tell your son this, the stock reported a quarter that people didn't like, and what happened? The stock went up. What does that tell you? We are finally at terra firma, and that is not one of those companies that's going to be, it does have some tariff problems, but not many. And what I would emphasize to you about Chipotle, it's never going to be cheap, but it's rarely down this long.' A chef plating up a wide variety of dishes for a restaurant chain. Overall, CMG ranks 9th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of CMG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
2 hours ago
- Yahoo
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines ROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, and Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, today announced a strategic collaboration aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing. This collaboration combines the MaxCyte ExPERT™ platform and proven Flow Electroporation® technology, widely recognized for its efficient and scalable transfection capabilities, utilized in over 19 active clinical and commercial programs, with Ori's innovative next-generation cell therapy manufacturing platform, IRO® (ee-RO). The collaboration will specifically evaluate how the IRO platform can optimize the yield and streamline the manufacturing timelines of MaxCyte-engineered primary T cells compared to traditional post-electroporation cell expansion processes. As a key component of this joint effort, Ori and MaxCyte have selected CD19 CAR expression via CRISPR knock-in in activated T cells as the test system for initial evaluation. MaxCyte's technology offers unparalleled flexibility and efficiency in transfecting cells at clinical scale, seamlessly integrating with diverse upstream and downstream processes within cell therapy workflows. The IRO platform complements this by introducing automated fluid handling, customizable mixing, and the OriConnect® tubeless sterile connection system, enhancing cell culture efficiency and scalability. Together, these complementary technologies provide therapy developers with a powerful toolkit to achieve clinically relevant quantities of gene-edited T cells more rapidly and efficiently. Maher Masoud, President and CEO of MaxCyte, commented, 'We are excited to collaborate with the team at Ori Biotech, combining our respective strengths and innovative technologies to significantly enhance manufacturing processes. This partnership underscores our commitment to enabling therapy developers to more effectively address the evolving demands of cell therapy manufacturing, ultimately accelerating the availability of transformative treatments for patients.''Our partnership with MaxCyte is another example of Ori's dedication to providing flexible and scalable solutions that address critical challenges in cell and gene therapy manufacturing,' said Jason C. Foster, CEO of Ori Biotech. 'By integrating modular, best-of-breed technologies, we're raising the standard of manufacturing by enhancing commercial viability. Ultimately, this collaboration helps bring cell therapies to patients faster, more reliably, and at greater scale.' Through their shared commitment to innovation and industry collaboration, MaxCyte and Ori Biotech are enabling developers of advanced therapies to adopt integrated, best-of-breed solutions, accelerating the path from research to commercialization and making next-generation treatments more accessible to patients globally. About MaxCyte At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at and follow us on X and LinkedIn. About Ori Biotech Ori Biotech is a London and Philadelphia-based manufacturing technology company on a mission to enable widespread patient access to life-saving cell and gene therapies. IRO®, Ori's next-generation manufacturing platform automates better biology, accelerates product development and enables therapy developers to scale their products' clinical and commercial impact by seamlessly transitioning from R&D to GMP on one platform. The promise of the innovative Ori platform is to automate cell therapy manufacturing, increasing throughput, improving quality and decreasing costs by combining proprietary hardware, consumables, software, data and analytics. For news and updates, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated benefits, outcomes, and impact of the collaboration between MaxCyte and Ori Biotech; the potential for improving clinical success and commercial viability through new manufacturing standards; and the intention to accelerate development timelines, increase access to next-generation cell therapies, and deliver transformative treatments to patients globally. These statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which MaxCyte operates, as well as management's current beliefs and assumptions. Words such as 'aims,' 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'may,' 'will,' 'should,' 'continue,' and variations of such words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions that are difficult to predict and are often beyond the control of the companies involved. Actual outcomes and results may differ materially from those expressed or implied in these forward-looking statements due to various factors, including changes in market conditions, technological advancements, regulatory developments, and the success of ongoing research and evaluation efforts. Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended May 8, 2025. These documents are available through the Investor Menu, Financials section, under 'SEC Filings' on the Investors page of our website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, MaxCyte does not undertake any obligation to update or revise any forward-looking statements to reflect new information, events, or circumstances after the date of this release. MaxCyte Contacts: US IR AdviserGilmartin GroupDavid Deuchler, CFA+1 415-937-5400ir@ Oak Street CommunicationsKristen Whitekristen@ Nominated Adviser and Joint Corporate BrokerPanmure LiberumEmma Earl / Freddy CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500 UK IR AdviserICR HealthcareMary-Jane ElliottChris Welsh+44 (0)203 709 5700maxcyte@ Ori Biotech Contact: Debby Betzmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hypebeast
4 hours ago
- Hypebeast
ASICS GT-2160 'Black/Morpho' Delivers Bold Contrast and Retro Appeal
Name:ASICS GT-2160 'Black/Morpho'Colorway:'Black/Morpho'SKU:1203A275-003MSRP:$130 USDRelease Date:Available NowWhere to Buy:ASICS TheASICSGT-2160receives a vibrant and intriguing addition with its new 'Black/Morpho' colorway. This iteration continues to pay homage to the technical design language of the GT-2000 series from the early 2010s, while its colorway draws inspiration from the striking black morpho tetra fish. The silhouette combines a stealthy black mesh upper with vivid green and blue overlays, creating a bold visual contrast that highlights the shoe's intricate details. Metallic silver elements are strategically incorporated into the design, further elevating the visual appeal, all sitting atop an off-white sole unit that completes the dynamic look. Emblematic features from the GT-2000 are also carried over, including a segmented midsole structure and visible GEL® technology inserts. This combination not only creates an industrial aesthetic but also provides advanced cushioning properties, enhancing comfort.
